Key Highlights

  • Revenue was USD 35.12 million against an estimate of USD 4.34 million.
  • Loss per share was USD 0.27 against an estimate of a USD 0.37 loss.
  • LISRAYA net product Revenue was USD 30.97 million for the quarter.
  • Cash and marketable securities were approximately USD 4.2 billion.

Roivant Sciences (NASDAQ:ROIV) reported revenue of USD 35.12 million for the quarter ended September 30, 2026, against an estimate of USD 4.34 million. The loss per share was USD 0.27, compared with an estimate of a USD 0.37 loss and a USD 0.17 loss a year earlier.

Net loss was USD 137.21 million, against USD 166.04 million in the prior-year quarter. The loss from operations was USD 268.05 million, compared with USD 306.23 million. Management called it a transformational quarter with the commercial launch of LISRAYA.

LISRAYA Launch

LISRAYA, also known as brepocitinib, was approved by the FDA in August 2026 for the treatment of adults with dermatomyositis. The filing states the company launched the product and began to generate product revenue, with net product revenue of USD 30.97 million.

Management said the quarter reflected roughly five weeks on the market from approval and that USD 31 million of net revenue reflected strong initial demand. It said hundreds of patients were on paid drug at the end of the quarter and that revenue is recorded when specialty pharmacies buy the drug from the company. It said that drug has all been dispensed since the end of the quarter, that it continues to see strong uptake, and that initial patient and prescriber feedback is strong while noting it is early in the launch.

Operating Expenses and Pipeline Updates

Total operating expenses were USD 303.17 million, against USD 307.80 million a year earlier. Research and Development expenses were USD 105.96 million, compared with USD 92.75 million. Selling, general and administrative share-based compensation was USD 71.33 million, against USD 70.83 million. For the six months, total operating expenses were USD 670.997 million, against USD 594.896 million, and the loss from operations was USD 634.04 million, against USD 591.16 million. Six-month net loss was USD 427.82 million, or USD 0.53 per share, against USD 439.95 million, or USD 0.49 per share.

Management also said the company did not succeed in a study in cutaneous lupus erythematosus earlier in the quarter. It highlighted data for mosliciguat in pulmonary hypertension associated with interstitial lung disease, the start of a Phase 3 study there and an ongoing combination study with Tyvaso.

Liquidity

Cash and cash equivalents were USD 1.64 billion and marketable securities were USD 2.57 billion at September 30, 2026. The filing states the company had cash, cash equivalents and marketable securities of approximately USD 4.2 billion.

The company's chief executive officer, Matthew Gline, participated in the earnings call, which management described as the last quarterly update of 2026.

Roivant Sciences Second Quarter 2026 Earnings: Key Takeaways

Roivant Sciences reported revenue of USD 35.12 million and a loss per share of USD 0.27 for the quarter ended September 30, 2026. LISRAYA net product revenue was USD 30.97 million, and cash, cash equivalents and marketable securities were approximately USD 4.2 billion.